Cover Image

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and...

Full description

Saved in:
Bibliographic Details
Main Authors: Moreau, Philippe (Author) , Hebraud, Benjamin (Author) , Facon, Thierry (Author) , Leleu, Xavier (Author) , Hulin, Cyrille (Author) , Hashim, Mahmoud (Author) , Hu, Yannan (Author) , Caillot, Denis (Author) , Benboubker, Lofti (Author) , Zweegman, Sonja (Author) , Merz, Maximilian (Author) , Weisel, Katja (Author) , Salwender, Hans (Author) , Mai, Elias K. (Author) , Goldschmidt, Hartmut (Author) , Bertsch, Uta (Author) , Vanquickelberghe, Véronique (Author) , Kampfenkel, Tobias (Author) , Boer, Carla de (Author) , Krotneva, Stanimira (Author) , Proskorovsky, Irina (Author) , He, Jianming (Author) , Lam, Annette (Author) , Lee, Charlene (Author) , Cote, Sarah (Author) , Sonneveld, Pieter (Author)
Format: Article (Journal)
Language:English
Published: February 2021
In: Immunotherapy
Year: 2021, Volume: 13, Issue: 2, Pages: 143-154
ISSN:1750-7448
DOI:10.2217/imt-2020-0266
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2217/imt-2020-0266
Verlag, lizenzpflichtig, Volltext: https://www.futuremedicine.com/doi/10.2217/imt-2020-0266
Get full text
Author Notes:Philippe Moreau, Benjamin Hebraud, Thierry Facon, Xavier Leleu, Cyrille Hulin, Mahmoud Hashim, Yannan Hu, Denis Caillot, Lofti Benboubker, Sonja Zweegman, Maximilian Merz, Katja Weisel, Hans Salwender, Elias K Mai, Hartmut Goldschmidt, Uta Bertsch, Véronique Vanquickelberghe, Tobias Kampfenkel, Carla de Boer, Stanimira Krotneva, Irina Proskorovsky, Jianming He, Annette Lam, Charlene Lee, Sarah Cote, and Pieter Sonneveld
Description
Summary:Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.
Item Description:Online veröffentlicht: 24 November 2020
Gesehen am 23.02.2024
Physical Description:Online Resource
ISSN:1750-7448
DOI:10.2217/imt-2020-0266

Similar Items